bioAffinity narrows cash runway to one month as losses widen despite 146% test sales surge

Filed May 11, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read

Key Changes

• high

  Cash runway shortened to June 2026 (one month from filing date) versus August 2025 in prior year, despite higher quarter-end cash balance. Accumulated deficit grew $15.9M to $72.2M as net loss widened 33% to $3.6M.

  MD&A: Liquidity; Risk Factors verify on EDGAR →
• high

  CyPath Lung unit sales jumped 146% year-over-year with revenue up 114% to $361K, but consolidated revenue fell 36% to $1.4M as pathology services revenue declined 34% following March 2025 strategic exit from unprofitable work.

  MD&A: Revenue verify on EDGAR →
• high

  Company enrolled first patient in pivotal clinical trial (NCT07168993) in March 2026, supported by Department of Defense at three military medical centers—a key regulatory milestone for CyPath Lung.

  MD&A: Clinical Development verify on EDGAR →